Literature DB >> 34310191

At Preeclampsia Diagnosis, Total Cell-Free DNA Concentration is Elevated and Correlates With Disease Severity.

Teodora R Kolarova1, Hilary S Gammill1, J Lee Nelson2,3, Christina M Lockwood4, Raj Shree1.   

Abstract

Background Placental derived cell-free DNA (cfDNA), widely utilized for prenatal screening, may serve as a biomarker for preeclampsia. To determine whether cfDNA parameters are altered in preeclampsia, we conducted a case-control study using prospectively collected maternal plasma (n=20 preeclampsia, n=22 normal) using our in-house validated prenatal screening assay. Methods and Results Isolated cfDNA was quantified, sequenced using Illumina NextSeq 500, and the placental-derived fraction was determined. Clinical and test characteristics were compared between preeclampsia and controls, followed by comparisons within the preeclampsia cohort dichotomized by cfDNA concentration. Lastly, cfDNA parameters in preeclampsia were correlated with markers of disease severity. Maternal age, body mass index, gestational age at delivery, cesarean rate, and neonatal birthweight were expectedly different between groups (P≤0.05). The placental-derived cfDNA fraction did not differ between groups (21.4% versus 16.9%, P=0.06); however, total cfDNA was more than 10 times higher in preeclampsia (1235 versus 106.5 pg/µL, P<0.001). This relationship persisted when controlling for important confounders (OR 1.22, 95% CI 1.04-1.43, P=0.01). The dichotomized preeclampsia group with the highest cfDNA concentration delivered earlier (33.2 versus 36.6 weeks, P=0.02) and had lower placental-derived fractions (9.1% versus 21.4%, P=0.04). Among preeclampsia cases, higher total cfDNA correlated with earlier gestational age at delivery (P=0.01) and higher maximum systolic blood pressure (P=0.04). Conclusions At diagnosis, total cfDNA is notably higher in preeclampsia, whereas the placental derived fraction remains similar to healthy pregnancies. In preeclampsia, higher total cfDNA correlates with earlier gestational age at delivery and higher systolic blood pressure. These findings may indicate increased release of cfDNA from maternal tissue injury.

Entities:  

Keywords:  cell‐free DNA; hypertension; preeclampsia; pregnancy

Year:  2021        PMID: 34310191     DOI: 10.1161/JAHA.121.021477

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  4 in total

1.  Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity.

Authors:  Raj Shree; Teodora R Kolarova; Hayley J MacKinnon; Christina M Lockwood; Suchitra Chandrasekaran
Journal:  Am J Obstet Gynecol MFM       Date:  2022-05-27

Review 2.  Circulating cell-free DNA for cancer early detection.

Authors:  Qiang Gao; Qiang Zeng; Zhijie Wang; Chengcheng Li; Yu Xu; Peng Cui; Xin Zhu; Huafei Lu; Guoqiang Wang; Shangli Cai; Jie Wang; Jia Fan
Journal:  Innovation (Camb)       Date:  2022-05-06

3.  Serum From Preeclamptic Women Triggers Endoplasmic Reticulum Stress Pathway and Expression of Angiogenic Factors in Trophoblast Cells.

Authors:  Karla R Castro; Karen M Prado; Aline R Lorenzon; Mara S Hoshida; Eliane A Alves; Rossana P V Francisco; Marcelo Zugaib; Aldilane L X Marques; Elaine C O Silva; Eduardo J S Fonseca; Alexandre U Borbely; Mariana M Veras; Estela Bevilacqua
Journal:  Front Physiol       Date:  2022-02-04       Impact factor: 4.566

4.  The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: a case report.

Authors:  Wei-Liang Chen; Emily Pao; James Owens; Ian Glass; Colin Pritchard; Brain H Shirts; Christina Lockwood; Ghayda M Mirzaa
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.